氯吡格雷抵抗及其对策

[1] Variability in Individual Responsiveness to Clopidogrel[J] . Dominick J. Angiolillo,Antonio Fernandez-Ortiz,Esther Bernardo,Fernando Alfonso,Carlos Macaya,Theodore A. Bass,Marco A. Costa.Journal of the American College of Cardiology . 2007 (14)

[2] Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus （OPTIMUS） Study[J] . Dominick J. Angiolillo,Steven B. Shoemaker,Bhaloo Desai,Hang Yuan,Ronald K. Charlton,Esther Bernardo,Martin M. Zenni,Luis A. Guzman,Theodore A. Bass,Marco A. Costa.Circulation . 2007 (6)

[3] Initial experience with an intravenous P2Y 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial[J] . Adam B. Greenbaum,Cindy L. Grines,John A. Bittl,Richard C. Becker,Dean J. Kereiakes,Ian C. Gilchrist,Jane Clegg,Jill E. Stankowski,Donna R. Grogan,Robert A. Harrington,Hakan Emanuelsson,W. Douglas Weaver.American Heart Journal . 2006 (3)

[4] Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (02) : 298 - 304

[5] Preclinical and clinical studies with selective reversible direct P2Y12 antagonists [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02) : 195 - 204

[6] Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 （Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty） Study[J] . Giuseppe Patti,Giuseppe Colonna,Vincenzo Pasceri,Leonardo Lassandro Pepe,Antonio Montinaro,Germano Di Sciascio.Circulation . 2005 (16)

[1] Variability in Individual Responsiveness to Clopidogrel[J] . Dominick J. Angiolillo,Antonio Fernandez-Ortiz,Esther Bernardo,Fernando Alfonso,Carlos Macaya,Theodore A. Bass,Marco A. Costa.Journal of the American College of Cardiology . 2007 (14)

[2] Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus （OPTIMUS） Study[J] . Dominick J. Angiolillo,Steven B. Shoemaker,Bhaloo Desai,Hang Yuan,Ronald K. Charlton,Esther Bernardo,Martin M. Zenni,Luis A. Guzman,Theodore A. Bass,Marco A. Costa.Circulation . 2007 (6)

[3] Initial experience with an intravenous P2Y 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial[J] . Adam B. Greenbaum,Cindy L. Grines,John A. Bittl,Richard C. Becker,Dean J. Kereiakes,Ian C. Gilchrist,Jane Clegg,Jill E. Stankowski,Donna R. Grogan,Robert A. Harrington,Hakan Emanuelsson,W. Douglas Weaver.American Heart Journal . 2006 (3)

[4] Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (02) : 298 - 304

[5] Preclinical and clinical studies with selective reversible direct P2Y12 antagonists [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (02) : 195 - 204

[6] Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 （Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty） Study[J] . Giuseppe Patti,Giuseppe Colonna,Vincenzo Pasceri,Leonardo Lassandro Pepe,Antonio Montinaro,Germano Di Sciascio.Circulation . 2005 (16)